背景:学术肿瘤学与工业之间的协作关系(制药,生物技术,\“omic,\“和医疗器械公司)对于肿瘤学的治疗发展至关重要;然而,关于参与和对这些关系的看法的研究有限。
方法:调查问题旨在评估学术肿瘤学与行业之间的关系。对美国临床肿瘤学会随机选择的1000名成员进行了电子调查,肿瘤学家的专业组织,引发受访者对肿瘤行业合作的看法。根据预先指定的计划对反应进行分析。
结果:有225名调查对象。大多数来自美国(70.0%),在学术机构工作(60.1%),在肿瘤内科工作(81.2%),与工业有积极关系(85.8%)。四分之一(26.7%)的受访者表示难以与行业合作者建立关系,大多数受访者(75%)没有报告在发展这些关系方面有导师。大多数受访者(85.3%)认为这些合作对他们的职业生涯很重要。受访者普遍认为科学完整性得到了保留(92%),大多数受访者(95%)对合作产品的质量几乎不关心。许多人(60%)对潜在的利益冲突表示担忧,如果有补偿关系的个人推广了用于临床护理/研究的行业产品,然而,大多数受访者(67%)表示,这些关系并不能影响他们与患者的互动.
结论:这项研究提供了表征临床医生之间协作关系性质的新数据,研究人员,和肿瘤学行业。尽管受访者认为这些合作是临床和学术肿瘤学的重要组成部分,围绕这些关系的正规教育或指导是罕见的。围绕利益冲突的相互矛盾的发现凸显了在这一领域进行更专注研究的重要性。
结论:医疗保健行业的商业企业在癌症研究和护理中发挥着核心作用,推动新医学检测的发展,毒品,和设备。临床医生之间有效的工作关系,研究人员,这些行业合作伙伴可以促进创新研究并增强患者护理。迄今为止,对这些合作的研究受到限制。通过向癌症临床医生和研究人员分发问卷,我们发现大多数参与者认为这些关系很有价值,尽管他们发现建立这种关系具有挑战性,部分原因是该领域教育计划的差距。我们的发现还强调,需要围绕这些关系可能带来的潜在偏见采取进一步的政策。
Collaborative relationships between academic oncology and industry (pharmaceutical, biotechnology, \"omic,\" and medical device companies) are essential for therapeutic development in oncology; however, limited research on engagement in and perceptions of these relationships has been done.
Survey questions were developed to evaluate relationships between academic oncology and industry. An electronic survey was delivered to 1000 randomly selected members of the American Society of Clinical Oncology, a professional organization for oncologists, eliciting respondents\' views around oncology-industry collaborations. The responses were analyzed according to prespecified plans.
There were 225 survey respondents. Most were from the United States (70.0%), worked at an academic institution (60.1%), worked in medical oncology (81.2%), and had an active relationship with industry (85.8%). One quarter (26.7%) of respondents reported difficulty establishing a relationship with industry collaborators, and most respondents (75%) did not report having had mentorship in developing these relationships. The majority (85.3%) of respondents considered these collaborations important to their careers. Respondents generally thought that scientific integrity was preserved (92%), and most respondents (95%) had little concern over the quality of the collaborative product. Many (60%) shared concerns over potential conflict of interest if an individual with a compensated relationship promoted an industry product for clinical care/research, yet most respondents (67%) stated these relationships did not shape their interactions with patients.
This study provides novel data characterizing the nature of collaborative relationships between clinicians, researchers, and industry in oncology. Although respondents considered these collaborations an important part of clinical and academic oncology, formal education or mentorship around these relationships was rare. Conflicting findings around conflict of interest highlight the importance of more dedicated research in this area.
Business enterprises in health care play a central role in cancer research and care, driving the development of new medical testing, drugs, and devices. Effective working relationships among clinicians, researchers, and these industry partners can promote innovative research and enhance patient care. Study of these collaborations has been limited to date. Through distribution of a questionnaire to cancer clinicians and researchers, we found that most participants consider these relationships valuable, though they find establishing such relationships challenging partly because of gaps in educational programs in this area. Our findings also highlight the need for further policy around the potential bias these relationships can introduce.